Want to see SNDX full AI Analyst Report?
Syndax Pharmaceuticals (SNDX) Stock Forecast & Price Target
1,059 Followers
SNDX Analyst Ratings
Strong Buy
7Buy1Hold0Sell
Based on 8 analysts giving stock ratings to Syndax Pharmaceuticals in the past 3 months
SNDX Stock 12 Month Forecast
Average Price Target
$37.38▲(257.66% Upside)Based on 8 Wall Street analysts offering 12 month price targets for Syndax Pharmaceuticals in the last 3 months. The average price target is $37.38 with a high forecast of $57.00 and a low forecast of $23.00. The average price target represents a 257.66% change from the last price of $10.45.
Past 12 Months12 Month ForecastJan2026Oct2026
High$57.00
Average$37.38
Low$23.00
Highest Price TargetHighest$57.00Average Price Target$37.38Lowest Price TargetLowest$23.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Andres Y. Maldonado | H.C. Wainwright | $36 | buy | 244.50%Upside | Reiterated | 11/05/26 | ||
| Stephen Willey | Stifel Nicolaus | $40 | buy | 282.78%Upside | Assigned | 11/05/26 | ||
 Unknown AnalystNot Ranked | B. Riley Securities | $33 | buy | 215.79%Upside | Initiated | 11/04/26 | ||
| Etzer Darout | Barclays | $37 | buy | 254.07%Upside | Reiterated | 11/03/26 | ||
| Jason Zemansky | Bank of America Securities | $23 | buy | 120.10%Upside | Reiterated | 11/02/26 | ||
| David Dai | UBS | $33 | hold | 215.79%Upside | Reiterated | 11/02/26 | ||
| Yigal Nochomovitz | Citi | $57 | buy | 445.45%Upside | Reiterated | 11/02/26 | ||
| Anupam Rama | J.P. Morgan | $44→$40 | buy | 282.78%Upside | Reiterated | 08/11/26 | ||
| Phil Nadeau | TD Cowen | ― | buy | ― | Reiterated | 08/04/26 | ||
| Corinne Johnson | Goldman Sachs | $34 | buy | 225.36%Upside | Reiterated | 07/14/26 | ||
| Bradley Canino | Guggenheim | $31 | buy | 196.65%Upside | Reiterated | 07/14/26 | ||
| Faisal Khurshid | Jefferies | $40→$37 | buy | 254.07%Upside | Reiterated | 05/01/26 | ||
| Salim Syed | Mizuho Securities | $45→$43 | buy | 311.48%Upside | Reiterated | 03/30/26 | ||
| Justin Zelin | BTIG | $56 | buy | 435.89%Upside | Reiterated | 01/02/26 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Andres Y. MaldonadoH.C. Wainwright | BuyReiterated$36 | 11/05/26 | 244.50%Upside | ||
| Stephen WilleyStifel Nicolaus | BuyAssigned$40 | 11/05/26 | 282.78%Upside | ||
| Unknown AnalystB. Riley SecuritiesNot Ranked | BuyInitiated$33 | 11/04/26 | 215.79%Upside | ||
| Etzer DaroutBarclays | BuyReiterated$37 | 11/03/26 | 254.07%Upside | ||
| Jason ZemanskyBank of America Securities | BuyReiterated$23 | 11/02/26 | 120.10%Upside | ||
| David DaiUBS | HoldReiterated$33 | 11/02/26 | 215.79%Upside | ||
| Yigal NochomovitzCiti | BuyReiterated$57 | 11/02/26 | 445.45%Upside | ||
| Anupam RamaJ.P. Morgan | BuyReiterated$44→$40 | 08/11/26 | 282.78%Upside | ||
| Phil NadeauTD Cowen | BuyReiterated | 08/04/26 | ― | ||
| Corinne JohnsonGoldman Sachs | BuyReiterated$34 | 07/14/26 | 225.36%Upside | ||
| Bradley CaninoGuggenheim | BuyReiterated$31 | 07/14/26 | 196.65%Upside | ||
| Faisal KhurshidJefferies | BuyReiterated$40→$37 | 05/01/26 | 254.07%Upside | ||
| Salim SyedMizuho Securities | BuyReiterated$45→$43 | 03/30/26 | 311.48%Upside | ||
| Justin ZelinBTIG | BuyReiterated$56 | 01/02/26 | 435.89%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Syndax Pharmaceuticals
3 Months
Success Rate10/19 ratings generated profit
53%
Average Return
+6.64%
Copying Justin Zelin's trades and holding each position for 3 Months would result in 52.63% of your transactions generating a profit, with an average return of +6.64% per trade.
1 Year
Success Rate8/16 ratings generated profit
50%
Average Return
-8.26%
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -8.26% per trade.
2 Years
Success Rate10/27 ratings generated profit
37%
Average Return
-4.67%
Copying Jason Zemansky's trades and holding each position for 2 Years would result in 37.04% of your transactions generating a profit, with an average return of -4.67% per trade.
SNDX Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 18 | 18 | 14 | 14 | 13 |
| Buy | 6 | 7 | 7 | 2 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 24 | 25 | 21 | 16 | 14 |
In the current month, SNDX has received 13 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. SNDX average Analyst price target in the past 3 months is 37.38.
SNDX Financial Forecast
High$-0.38
Consensus$-0.53
Low$-0.61
SNDX Earnings Forecast
Next quarter’s earnings estimate for SNDX is -$0.53 with a range of -$0.61 to -$0.38. The previous quarter’s EPS was -$0.55. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$128M
Consensus$95.1M
Low$87.3M
SNDX Sales Forecast
Next quarter’s sales forecast for SNDX is $95.10M with a range of $87.27M to $127.88M. The previous quarter’s sales results were $83.30M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
SNDX Stock Forecast FAQ
What is SNDX’s average 12-month price target, according to analysts?
Based on analyst ratings, Syndax Pharmaceuticals’s 12-month average price target is $37.38.
What is SNDX’s upside potential, based on the analysts’ average price target?
Syndax Pharmaceuticals has 257.66% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SNDX a Buy, Sell or Hold?
Syndax Pharmaceuticals has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
What is Syndax Pharmaceuticals’s price target?
The average price target for Syndax Pharmaceuticals is $37.38. This is based on 8 12-month price targets, issued in the past 3 months. The highest analyst price target is $57.00, the lowest forecast is $23.00. The average price target represents a 257.66% increase from the current price of $10.45.
What do analysts say about Syndax Pharmaceuticals?
Syndax Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Street analysts.
How can I buy shares of SNDX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
